7/24/2008 3:09:38 PM
MONTREAL, July 24 /CNW Telbec/ - Akela Pharma Inc. (TSX: "AKL"), a drug
development company focused on developing therapies for the inhalation and
pain markets, today announced that it has been awarded a contract at its
PharmaForm subsidiary located in Austin, Texas, to process validate and
manufacture Phase III Registration Batches for Proellex(R), a drug product
developed by Repros Therapeutics, Inc (NASDAQ: "RPRX").
comments powered by